Amyris, Inc. (NASDAQ:AMRS) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Amyris in a report on Tuesday, May 23rd. Zacks Investment Research raised shares of Amyris from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 16th. Finally, Cowen and Company set a $4.00 target price on shares of Amyris and gave the company a “hold” rating in a report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $25.70.

Amyris (NASDAQ AMRS) traded up 1.21% during mid-day trading on Friday, reaching $2.50. The company’s stock had a trading volume of 206,047 shares. The company’s market cap is $94.02 million. The firm has a 50 day moving average price of $3.10 and a 200 day moving average price of $5.20. Amyris has a 52-week low of $0.21 and a 52-week high of $18.15.

Amyris (NASDAQ:AMRS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by $0.35. The firm had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $23.68 million. During the same quarter in the previous year, the firm earned ($0.06) EPS. The firm’s revenue was up 167.5% on a year-over-year basis. Equities research analysts anticipate that Amyris will post ($3.32) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Amyris, Inc. (AMRS) Upgraded to “Sell” at ValuEngine” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at

An institutional investor recently raised its position in Amyris stock. Bank of New York Mellon Corp raised its stake in shares of Amyris, Inc. (NASDAQ:AMRS) by 16.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,768 shares of the biotechnology company’s stock after buying an additional 4,603 shares during the period. Bank of New York Mellon Corp owned approximately 0.17% of Amyris worth $104,000 as of its most recent SEC filing. 19.79% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.